Last update Nov. 15, 2015
Very Low Risk
Non-glycosylated stimulating factor of granulocyte colonies (G-CSF) which is obtained by recombinant technology. It has similar action and indication than Filgrastim. The naturally occurring product is found in breast milk.
It is indicated for the treatment of cancer-related neutropenia and severe congenital neutropenia.
A very high molecular weight explains the insignificant or no excretion into milk that has been observed both with Lenograstim and Filgrastim.
Its low oral bioavailability hampers absorption into infant plasma from the breast milk ingested, as for their proteic nature it is degraded in the gastrointestinal tract, not being absorbed. Filgrastim is not absorbed by the infant's gut even during the neonatal period or prematurity.
The granulocyte colony-stimulating factor (Filgrastim) has been used in premature newborns, both on prevention and treatment of neonatal sepsis and/or necrotizing enterocolitis without adverse effects being observed among treated infants.
The bovine G-CSF is found in the usual diet of meat eaters.
We do not have alternatives for Lenograstim since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM